The Role of SATB2 as a Diagnostic Marker for Tumors of Colorectal Origin

被引:112
|
作者
Dragomir, Anca [1 ]
de Wit, Meike [2 ]
Johansson, Christine [3 ]
Uhlen, Mathias [4 ]
Ponten, Fredrik [1 ]
机构
[1] Uppsala Univ, Dept Immunol Genet & Pathol, S-75185 Uppsala, Sweden
[2] Vrije Univ Amsterdam Med Ctr, Dept Med Oncol, Amsterdam, Netherlands
[3] AlbaNova Univ Ctr, Atlas Antibodies AB, Stockholm, Sweden
[4] KTH Royal Inst Technol, Sci Life Lab, Stockholm, Sweden
关键词
Immunohistochemistry; Cytokeratin; 20; SATB2; Colorectal cancer; Cancer of unknown primary (CUP); PROTEIN EXPRESSION; UNKNOWN PRIMARY; CYTOKERATINS; 7; CDX2; ANTIBODY; ADENOCARCINOMAS; CANCER; IMMUNOREACTIVITY; METASTASES; CARCINOMAS; LIVER;
D O I
10.1309/AJCPWW2URZ9JKQJU
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Objectives: Immunohistochemistry is an important extension to clinical information and morphology, and prevails as an invaluable tool for establishing a correct cancer diagnosis in clinical diagnostic pathology. The applicability of immunohistochemistry is limited by the availability of validated cell- and cancer-type specific antibodies, rendering an unmet need to discover, test, and validate novel markers. The SATB2 protein is selectively expressed in glandular cells from the lower gastrointestinal tract and expression is retained in a large majority of primary and metastatic colorectal cancers. Methods: We analyzed the expression of SATB2 in all clinical cases (n = 840), in which immunohistochemistry for detection of CK20 was deemed necessary for a final diagnosis. Results: SATB2 showed a high sensitivity (93%) and specificity (77%) to determine a cancer of colorectal origin and in combination with CK7 and CK20, the specificity increased to 100%. Conclusions: We conclude that SATB2 provides a new and advantageous supplement for clinical differential diagnostics.
引用
收藏
页码:630 / 638
页数:9
相关论文
共 50 条
  • [1] SATB2 is a Novel Marker of Osteoblastic Differentiation and Colorectal Adenocarcinoma
    Ordonez, Nelson G.
    ADVANCES IN ANATOMIC PATHOLOGY, 2014, 21 (01) : 63 - 67
  • [2] The Role of SATB2 as a Diagnostic Marker of Sinonasal Intestinal-type Adenocarcinoma
    Skalova, Alena
    Sar, Aylin
    Laco, Jan
    Metelkova, Alena
    Miesbauerova, Marketa
    Steiner, Petr
    Svajdler, Marian
    Michal, Michal
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2018, 26 (02) : 140 - 146
  • [3] SATB2 Expression in Human Tumors
    Dum, David
    Kromm, Daniela
    Lennartz, Maximilian
    De Wispelaere, Noemi
    Buescheck, Franziska
    Luebke, Andreas M.
    Burandt, Eike
    Menz, Anne
    Kluth, Martina
    Hube-Magg, Claudia
    Hinsch, Andrea
    Hoeflmayer, Doris
    Weidemann, Soeren
    Fraune, Christoph
    Moeller, Katharina
    Lebok, Patrick
    Sauter, Guido
    Simon, Ronald
    Uhlig, Ria
    Wilczak, Waldemar
    Minner, Sarah
    Krech, Rainer
    Bernreuther, Christian
    Marx, Andreas
    Steurer, Stefan
    Jacobsen, Frank
    Clauditz, Till
    Krech, Till
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2023, 147 (04) : 451 - 464
  • [4] Diagnostic accuracy of SATB2 in identifying primary and metastatic colorectal carcinoma: a comparative immunohistochemical study
    Elnady, Manar S.
    Eltatawy, Faika A.
    Nosseir, Azima G.
    Zamzam, Yomna A.
    El-Guindy, Dina M.
    ECANCERMEDICALSCIENCE, 2022, 16
  • [5] SATB2 is a supplementary immunohistochemical marker to CDX2 in the diagnosis of colorectal carcinoma metastasis in an unknown primary
    Dabir, Parag Deepak
    Svanholm, Hans
    Christiansen, Jens Johannes
    APMIS, 2018, 126 (06) : 494 - 500
  • [6] Dual Stain With SATB2 and CK20/Villin Is Useful to Distinguish Colorectal Carcinomas From Other Tumors
    Li, Zaibo
    Rock, Jonathan B.
    Roth, Rachel
    Lehman, Amy
    Marsh, William L.
    Suarez, Adrian
    Frankel, Wendy L.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2018, 149 (03) : 241 - 246
  • [7] SATB2 is a sensitive marker for lower gastrointestinal well-differentiated neuroendocrine tumors
    Li, Zhongwu
    Yuan, Jing
    Wei, Lixin
    Zhou, Lixin
    Mei, Kaiyong
    Yue, Junqiu
    Gao, Hongwen
    Zhang, Miao
    Jia, Ling
    Kang, Qiang
    Huang, Xiaozheng
    Cao, Dengfeng
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2015, 8 (06): : 7072 - 7082
  • [8] SATB2 Versus CDX2 A Battle Royale for Diagnostic Supremacy in Mutinous Tumors
    Brettfeld, Stefan M.
    Ramos, Benjamin D.
    Berry, Ryan S.
    Martin, David R.
    Hanson, Joshua A.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2019, 143 (09) : 1119 - 1125
  • [9] SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type
    Moh, Michelle
    Krings, Gregor
    Ates, Deniz
    Aysal, Anil
    Kim, Grace E.
    Rabban, Joseph T.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2016, 40 (03) : 419 - 432
  • [10] SATB2 and MDM2 Immunoexpression and Diagnostic Role in Primary Osteosarcomas of the Jaw
    Owosho, Adepitan A.
    Ladeji, Adeola M.
    Adesina, Olufunlola M.
    Adebiyi, Kehinde E.
    Olajide, Mofoluwaso A.
    Okunade, Toluwaniyin
    Palmer, Jacob
    Kehinde, Temitope
    Vos, Jeffrey A.
    Cole, Grayson
    Summersgill, Kurt F.
    DENTISTRY JOURNAL, 2022, 10 (01)